Ionis Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Lumentum shares fall after hitting 52-week high
- Getty Images to go private via prepackaged Chapter 11 restructuring
Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 14c, Revenues Miss
November 6, 2018 7:17 AM ESTIonis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.03), $0.14 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $145 million versus the consensus estimate of $152.68 million.
"We enter the fourth quarter in a position of financial strength, driven by strong worldwide SPINRAZA sales. In addition, we achieved numerous successes during the quarter... More



